MX2021002112A - Uso de agonistas del receptor alfa-2-adrenergico para mejorar la vision. - Google Patents
Uso de agonistas del receptor alfa-2-adrenergico para mejorar la vision.Info
- Publication number
- MX2021002112A MX2021002112A MX2021002112A MX2021002112A MX2021002112A MX 2021002112 A MX2021002112 A MX 2021002112A MX 2021002112 A MX2021002112 A MX 2021002112A MX 2021002112 A MX2021002112 A MX 2021002112A MX 2021002112 A MX2021002112 A MX 2021002112A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- adrenergic receptor
- receptor agonists
- improving vision
- visual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720671P | 2018-08-21 | 2018-08-21 | |
| PCT/US2019/047305 WO2020041340A1 (en) | 2018-08-21 | 2019-08-20 | The use of alpha-2-adrenergic receptor agonists for improving vision |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002112A true MX2021002112A (es) | 2021-07-16 |
Family
ID=67841225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002112A MX2021002112A (es) | 2018-08-21 | 2019-08-20 | Uso de agonistas del receptor alfa-2-adrenergico para mejorar la vision. |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20210205273A1 (enExample) |
| EP (1) | EP3840750A1 (enExample) |
| JP (1) | JP2021534217A (enExample) |
| KR (1) | KR20210047323A (enExample) |
| CN (1) | CN112823003A (enExample) |
| AR (1) | AR115991A1 (enExample) |
| AU (1) | AU2019325486A1 (enExample) |
| BR (1) | BR112021003295A2 (enExample) |
| CA (1) | CA3110318A1 (enExample) |
| CL (1) | CL2021000440A1 (enExample) |
| CO (1) | CO2021003460A2 (enExample) |
| IL (1) | IL280990A (enExample) |
| MX (1) | MX2021002112A (enExample) |
| PH (1) | PH12021550372A1 (enExample) |
| SG (1) | SG11202101730SA (enExample) |
| TW (1) | TW202021584A (enExample) |
| WO (1) | WO2020041340A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023514732A (ja) * | 2020-02-20 | 2023-04-07 | アラーガン、インコーポレイテッド | アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用 |
| WO2022182740A1 (en) | 2021-02-24 | 2022-09-01 | Ocular Therapeutix, Inc. | Intracanalicular depot inserter device |
| AU2024217271A1 (en) * | 2023-02-08 | 2025-09-18 | Bausch + Lomb Ireland Limited | Alpha-2-adrenergic agonists for improving vision |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| KR102337046B1 (ko) | 2010-01-22 | 2021-12-08 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| WO2012149381A1 (en) * | 2011-04-28 | 2012-11-01 | Alpha Synergy Development, Inc. | Compositions and methods for improving night vision |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| ES2751681T3 (es) | 2013-03-15 | 2020-04-01 | Allergan Inc | Implante intraocular que contiene prostamida |
| EP2978406A1 (en) | 2013-03-27 | 2016-02-03 | Forsight Vision5, Inc. | Bimatoprost ocular silicone inserts and methods of use thereof |
| WO2014165308A2 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| CN103338483B (zh) * | 2013-07-24 | 2016-08-10 | 成都西加云杉科技有限公司 | 数据分流方法、数据分流设备及异构网络 |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| US11077053B2 (en) * | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
-
2019
- 2019-08-20 EP EP19762588.2A patent/EP3840750A1/en not_active Withdrawn
- 2019-08-20 BR BR112021003295-9A patent/BR112021003295A2/pt not_active IP Right Cessation
- 2019-08-20 AU AU2019325486A patent/AU2019325486A1/en not_active Abandoned
- 2019-08-20 TW TW108129699A patent/TW202021584A/zh unknown
- 2019-08-20 WO PCT/US2019/047305 patent/WO2020041340A1/en not_active Ceased
- 2019-08-20 US US17/055,922 patent/US20210205273A1/en not_active Abandoned
- 2019-08-20 CN CN201980065608.3A patent/CN112823003A/zh active Pending
- 2019-08-20 JP JP2021510070A patent/JP2021534217A/ja active Pending
- 2019-08-20 MX MX2021002112A patent/MX2021002112A/es unknown
- 2019-08-20 CA CA3110318A patent/CA3110318A1/en active Pending
- 2019-08-20 SG SG11202101730SA patent/SG11202101730SA/en unknown
- 2019-08-20 KR KR1020217008132A patent/KR20210047323A/ko not_active Withdrawn
- 2019-08-21 AR ARP190102374A patent/AR115991A1/es not_active Application Discontinuation
-
2021
- 2021-02-21 IL IL280990A patent/IL280990A/en unknown
- 2021-02-22 PH PH12021550372A patent/PH12021550372A1/en unknown
- 2021-02-22 CL CL2021000440A patent/CL2021000440A1/es unknown
- 2021-03-17 CO CONC2021/0003460A patent/CO2021003460A2/es unknown
- 2021-06-30 US US17/364,470 patent/US20220160623A1/en not_active Abandoned
- 2021-10-29 US US17/452,963 patent/US20220288031A1/en not_active Abandoned
-
2024
- 2024-03-08 US US18/599,800 patent/US20240358682A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL280990A (en) | 2021-04-29 |
| CA3110318A1 (en) | 2020-02-27 |
| WO2020041340A1 (en) | 2020-02-27 |
| CL2021000440A1 (es) | 2021-09-20 |
| EP3840750A1 (en) | 2021-06-30 |
| KR20210047323A (ko) | 2021-04-29 |
| BR112021003295A2 (pt) | 2021-05-18 |
| US20220288031A1 (en) | 2022-09-15 |
| AR115991A1 (es) | 2021-03-17 |
| SG11202101730SA (en) | 2021-03-30 |
| US20240358682A1 (en) | 2024-10-31 |
| AU2019325486A1 (en) | 2021-03-25 |
| US20210205273A1 (en) | 2021-07-08 |
| JP2021534217A (ja) | 2021-12-09 |
| PH12021550372A1 (en) | 2021-11-29 |
| TW202021584A (zh) | 2020-06-16 |
| CO2021003460A2 (es) | 2021-04-08 |
| CN112823003A (zh) | 2021-05-18 |
| US20220160623A1 (en) | 2022-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| PH12021550621A1 (en) | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness | |
| MX2020011301A (es) | Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares. | |
| PH12021550620A1 (en) | Ophthalmic composition for treatment of dry eye disease | |
| PH12021550372A1 (en) | The use of alpha-2-adrenergic receptor agonists for improving vision | |
| MX2020011562A (es) | Agonistas del receptor de la hormona tiroidea y usos de los mismos. | |
| MX2011013060A (es) | Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas. | |
| HK1258588A1 (zh) | 用於治疗眼科疾病的化合物和制剂 | |
| MX2019004468A (es) | Uso de lentes de contacto en el tratamiento de una afeccion oftalmologica. | |
| EA201100393A1 (ru) | Применение усиливающих агентов, возможно связанных с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы | |
| RU2015134858A (ru) | Конфигурация линзы, не зависящей от размера зрачка, и способ для предотвращения и/или замедления прогрессирования миопии | |
| EP2778749A3 (en) | Presbyopia lens with pupil size correction based on level of refractive error | |
| MY196448A (en) | Anti-Htra1 Antibodies and Methods of use Thereof | |
| MX2025001445A (es) | Anticuerpos monoclonales anti-trkb y metodos de uso | |
| MX2021013447A (es) | Composiciones y procedimientos para el tratamiento de enfermedades oculares. | |
| CL2016002827A1 (es) | Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos. | |
| CY1124538T1 (el) | Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης | |
| EA201690532A1 (ru) | Не содержащий консерванта офтальмологический фармацевтический состав | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
| MX2021014357A (es) | Metodos y formulaciones para tratar trastornos de la vision. | |
| EA202192183A1 (ru) | Композиции, обладающие активностью удаления липофусцина из клеток сетчатки | |
| MX381356B (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| MX2020011535A (es) | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. | |
| MX2022010317A (es) | Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision. | |
| EP4652999A3 (en) | Liquid depot for non-invasive sustained delivery of agents to the eye |